News Category
Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 study and is preparing a response while...
Lantern Pharma's upcoming presentation at the ThinkEquity Conference underscores the growing investor interest in AI-powered oncology drug development...
Helus Pharma will host an investor presentation on October 21, 2026, to highlight its Phase 3 major depressive disorder candidate HLP003 and Phase 2 g...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a firs...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies (NAMs) that could accelerate clinical advancement, cut costs and ...
Nutriband Inc. has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating methods for its AV...
Lantern Pharma secures Taiwan regulatory and IRB approvals to open Part 2 of its Phase 2 HARMONIC trial, potentially accelerating development of LP-30...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its lead multiple sclerosis drug Lucid-MS into a phase 2 trial, te...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate the development of its an...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation for gout, toward a New Drug Application with the FDA, potentially offering...
Quantum BioPharma's agreement with Thermo Fisher for its Phase 2 Lucid-MS trial marks a critical step toward developing a first-in-class treatment for...
Telomir Pharmaceuticals' $5.6 million PIPE financing, including a $1 million investment from John Paul DeJoria, will fund the clinical development of ...
NanoViricides will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, showcasing its broad-spectrum antiviral NV-387, which is in Phase ...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher for its Phase 2 Lucid-MS trial signals a critical step toward developing a first-in-cl...
A new study reveals that the skull contains lymph node-like structures that may serve as a local immune defense for the brain, opening potential new a...
Kairos Pharma reported positive interim Phase 2 data showing ENV-105 plus apalutamide significantly improved progression-free survival in metastatic c...
AXIM Biotechnologies has submitted a 510(k) to the FDA for a next-generation lateral-flow tear lactoferrin test that could bring objective, 10-minute ...
GeoVax will present its next-generation MVA-X single-dose vaccine and continuous cell-line manufacturing platform at World Vaccine Congress Europe 202...
The Global Markets Forum (Hybrid) on October 7-8, 2026, will feature 19 companies from around the world presenting live and virtually, offering invest...
NHS England's new rapid brain tumor test drastically reduces diagnosis time, potentially accelerating access to innovative treatments from companies l...
Oncotelic Therapeutics opens registration for its AI-powered BIO REBOOT initiative and announces two PDAOAI presentations at a major drug discovery co...
NanoViricides has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral ...
Certified-PEP's emphasis on U.S.-made research peptides and independent batch testing through Vanguard Laboratory addresses a critical need for verifi...
Philip Ashton-Rickardt, a veteran biotech leader, argues that effective scientific leadership depends on balancing conviction with flexibility and tra...
A new blood-based method for identifying cancer-specific proteins could eliminate the need for surgical tumor samples in developing personalized immun...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter detailing the advancement of its abuse-deterren...
Regentis Biomaterials is advancing a regenerative solution for knee cartilage repair that aims to restore durable, hyaline-like cartilage rather than ...
HealthLynked's partnership with DRCARE247 will integrate virtual care directly into its mobile app and website, creating a seamless AI-to-provider exp...
Stonegate Capital Partners' updated coverage highlights Incannex Healthcare's progress in clinical execution and the implications for its lead asset I...
Lantern Pharma's $4 million registered direct offering provides essential capital to advance its AI-native precision oncology therapies, highlighting ...
Onco-Innovations advances its cancer drug candidate ONC010 toward clinical trials by completing API scale-up, securing financing, and strengthening it...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial in multiple sclerosis patients, while the company also holds a 20% stake and a 7% royalty str...
Silo Pharma's AI subsidiary QwikAgents now supports NVIDIA API keys and Hermes runtime, giving customers more flexibility and potentially accelerating...
Quantum BioPharma's Lucid-MS multiple sclerosis drug advances to Phase 2 testing while its alcohol metabolism product unbuzzd(TM) offers a 7% royalty ...
BIOT's non-exclusive appointment as CelSiege's representative for the IN01 cancer immunotherapy in Japan and China opens new business development oppo...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate beyond discovery, reinforcing its oncology pipeline and intellectual property ...
NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval to begin Phase II trials of NV-387 Oral Gummies for Mpox and Ebola in the D...
Lantern Pharma's $4 million registered direct offering provides essential working capital to advance its AI-powered oncology drug development, highlig...
The CDC's report of likely sustained Clade Ib mpox transmission in the U.S. highlights the need for vaccine preparedness and diversified supply, as Ge...
Creative Biolabs integrates glycoprotein development with glycan characterization, offering tailored analytical strategies to address glycosylation he...
Helix BioPharma Corp. has appointed four new directors with deep expertise in biotechnology, finance, and commercialization, a governance overhaul tha...
Viromed Medical AG reported progress in product development and market launch for its cold plasma technologies in H1 2026, including regulatory approv...
Discovery of a key protein driving glioblastoma growth could lead to new treatments for the deadliest brain cancer, as companies like CNS Pharmaceutic...
NanoViricides has begun patient enrollment and dosing in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic ...
TransCode Therapeutics announced updated Phase 1a data showing a 71.4% stable disease rate and a favorable safety profile for TTX-MC138 in advanced so...
Quantum BioPharma's FDA IND approval for Lucid-MS marks a pivotal step toward a phase 2 trial of a novel multiple sclerosis treatment with a unique me...
Certified-PEP emphasizes U.S. manufacturing, batch-level analytical testing, and accessible documentation to support the research community's need for...
Creative Biolabs has introduced a three-part antibody engineering framework to help biopharmaceutical researchers overcome immunogenicity, efficacy, a...
